Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · see citing works

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · see citing works

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686 · see citing works

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

Duration of Humoral Immunity to Common Viral and Vaccine Antigens

Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · see citing works

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192 · see citing works

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd2223 · Cited by 1,037 · see citing works

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822 · see citing works

Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications

Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754 · see citing works

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 727 · see citing works

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 623 · see citing works

The time course of the immune response to experimental coronavirus infection of man

Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598 · see citing works

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532 · see citing works

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho

Bryan, A. B., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 527 · see citing works

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525 · see citing works

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508 · see citing works

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint

Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa721 · Cited by 358 · see citing works

Impaired Antibody-Mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus

Habibi, M. S., Jóźwik, A., Makris, S., Dunning, J. W., Paras, A., DeVincenzo, J. P., de Haan, C. A. M., Wrammert, J., Openshaw, P., & Chiu, C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2256oc · Cited by 289 · see citing works

Somatically Hypermutated Plasmodium-Specific IgM+ Memory B Cells Are Rapid, Plastic, Early Responders upon Malaria Rechallenge

Krishnamurty, A. T., Thouvenel, C. D., Portugal, S., Keitany, G. J., Kim, K. S., Holder, A. A., Crompton, P. D., Rawlings, D. J., & Pepper, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.014 · Cited by 256 · see citing works

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227 · see citing works

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization

Salazar, E., Kuchipudi, S. V., Christensen, P. A., Eagar, T. N., Yi, X., Zhao, P., Jin, Z., Long, S. W., Olsen, R. J., Chen, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141206 · Cited by 213 · see citing works

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019Preprint

Zhao, J., Yuan, Q., Wang, H., Liu, W. Y., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3546052 · Cited by 208 · see citing works

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

Dieterle, M. E., Haslwanter, D., Bortz, R. H., Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.020 · Cited by 202 · see citing works

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Beaudoin-Bussières, G., Laumaea, A., Anand, S. P., Prévost, J., Gasser, R., Goyette, G., Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020) · mBio · doi:10.1128/mbio.02590-20 · Cited by 189 · see citing works

Origin and Function of Circulating Plasmablasts during Acute Viral Infections

Fink, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00078 · Cited by 181 · see citing works

IgA dominates the early neutralizing antibody response to SARS-CoV-2Preprint

Sterlin, D., Mathian, A., Miyara, M., et al. (2020) · medRxiv · doi:10.1101/2020.06.10.20126532 · Cited by 175 · see citing works

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent PatientsPreprint

Wang, X., Guo, X., Xin, Q., et al. (2020) · medRxiv · doi:10.1101/2020.04.15.20065623 · Cited by 171 · see citing works

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Temperton, N. J., Chan, P. K. S., Simmons, G., Zambon, M. C. F. A., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005) · Emerging infectious diseases · doi:10.3201/eid1103.040906 · Cited by 155 · see citing works

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Tai, W., Zhang, X., Drelich, A., Shi, J., Hsu, J. C., Luchsinger, L., Hillyer, C. D., Tseng, C.-T. K., Jiang, S., & Du, L. (2020) · Cell Research · doi:10.1038/s41422-020-0387-5 · Cited by 151 · see citing works

Neutralizing Antibody Response and SARS Severity

Ho, M., Chen, W., Chen, H., Lin, S.-F., Wang, M.-C., Di, J., Lu, Y., Liu, C., Chang, S., Chao, C.-L., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1111.040659 · Cited by 138 · see citing works

Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections

Lei, Q., Li, Y., Hou, H., Wang, F., Ouyang, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Xu, Z., Zhang, B., et al. (2020) · Allergy · doi:10.1111/all.14622 · Cited by 128 · see citing works

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1823890 · Cited by 122 · see citing works

The Multifaceted B Cell Response to Influenza Virus

Lam, J. H., & Baumgarth, N. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801208 · Cited by 119 · see citing works

Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform

Chu, H. Y., Englund, J. A., Starita, L. M., Famulare, M., Brandstetter, E., Nickerson, D. A., Rieder, M. J., Adler, A., Lacombe, K., Kim, A. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008646 · Cited by 99 · see citing works

Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies

Arevalo, C. P., Sage, V. L., Bolton, M. J., Eilola, T., Jones, J. E., Kormuth, K. A., Nturibi, E. M., Balmaseda, Á., Gordon, A. L., Lakdawala, S. S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920321117 · Cited by 98 · see citing works

Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak

Dingens, A. S., Crawford, K. H. D., Adler, A., Steele, S. L., Lacombe, K., Eguia, R. T., Amanat, F., Walls, A. C., Wolf, C. R., Murphy, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18178-1 · Cited by 68 · see citing works

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19Preprint

Wu, J., Liang, B., Chen, C., Wang, H., Fang, Y., Shěn, S., Yang, X., Wang, B., Chen, L., Chen, Q., et al. (2020) · medRxiv · doi:10.1101/2020.07.21.20159178 · Cited by 68 · see citing works

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Preprint

Walls, A. C., Fiala, B., Schäfer, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.11.247395 · Cited by 60 · see citing works

Immunologic perturbations in severe COVID-19/SARS-CoV-2 infectionPreprint

Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.18.101717 · Cited by 50 · see citing works

Antibody Dynamics of 2009 Influenza A (H1N1) Virus in Infected Patients and Vaccinated People in China

Wang, M., Yuan, J., Li, T., Liu, Y., Wu, J., Di, B., Chen, X., Xin-hong, X., Lu, E., Li, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016809 · Cited by 44 · see citing works

Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phasesPreprint

Yao, X., Liu, W. Y., Li, Z., Xiong, H., Su, Y., Li, T., Zhang, S., Zhang, X., Bi, Z., Deng, C.-X., et al. (2020) · medRxiv · doi:10.21203/rs.3.rs-327912/v1 · Cited by 23 · see citing works

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donorsPreprint

Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.16.206847 · Cited by 12 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822 · see citing works

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743 · see citing works

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525 · see citing works

The first 12 months of COVID-19: a timeline of immunological insights

Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 448 · see citing works

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351 · see citing works

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Bajema, K. L., Wiegand, R. E., Cuffe, K. M., Patel, S. V., Iachan, R., Lim, T. W., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 276 · see citing works

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258 · see citing works

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244 · see citing works

Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19

Teymouri, M., Mollazadeh, S., Mortazavi, H., Ghale-Noie, Z. N., Keyvani, V., Aghababaei, F., Hamblin, M. R., Abbaszadeh‐Goudarzi, G., Pourghadamyari, H., Hashemian, S. M. R., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153443 · Cited by 228 · see citing works

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Abe, K. T., Li, Z., Samson, R., Samavarchi‐Tehrani, P., Valcourt, E. J., Wood, H., Budylowski, P., Dupuis, A. P., Girardin, R. C., Rathod, B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142362 · Cited by 192 · see citing works

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults

Ward, H., Cooke, G., Atchison, C. J., Whitaker, M. D., Elliott, J., Moshe, M., Brown, J. C., Flower, B., Daunt, A., Ainslie, K. E. C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100098 · Cited by 193 · see citing works

A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike

Dadonaite, B., Crawford, K. H. D., Radford, C. E., Farrell, A. G., Yu, T. C., Hannon, W. W., Zhou, P.-P., Andrabi, R., Burton, D. R., Liu, L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.001 · Cited by 182 · see citing works

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Sakharkar, M., Rappazzo, C. G., Wieland-Alter, W. F., Hsieh, C.-L., Wrapp, D., Esterman, E. S., Kaku, C. I., Wec, A. Z., Geoghegan, J. C., McLellan, J. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg6916 · Cited by 174 · see citing works

Immunity to SARS‐CoV‐2 induced by infection or vaccination

Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 164 · see citing works

CD8 + T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19

Mallajosyula, V. V. A., Ganjavi, C., Chakraborty, S., McSween, A. M., Pavlovitch-Bedzyk, A. J., Wilhelmy, J., Nau, A. N., Manohar, M., Nadeau, K. C., & Davis, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg5669 · Cited by 161 · see citing works

SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort StudyPreprint

Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 148 · see citing works

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 154 · see citing works

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 130 · see citing works

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

Pang, N. Y., Pang, A. S., Chow, V. T. K., & Wang, D. Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00342-3 · Cited by 137 · see citing works

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020

Self, W. H., Tenforde, M. W., Stubblefield, W. B., Feldstein, L. R., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Prekker, M. E., Brown, S. M., Peltan, I. D., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6947a2 · Cited by 138 · see citing works

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 131 · see citing works

The scientific and ethical feasibility of immunity passports

Brown, R. C. H., Kelly, D. F., Wilkinson, D., & Savulescu, J. (2020) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(20)30766-0 · Cited by 111 · see citing works

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 121 · see citing works

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

Yu, Y.-L., Wang, M., Zhang, X.-A., Li, S.-F., Lu, Q.-Y., Zeng, H.-L., Hou, H., Li, H., Zhang, M.-Y., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 108 · see citing works

Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. G., Anderson, J., Paynter, R. A., & Mackey, K. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7547 · Cited by 112 · see citing works

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Yang, Y., Yang, M.-H., Peng, Y., Liang, Y.-J., Wei, J.-L., Xing, L., Guo, L., Li, X.-H., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 104 · see citing works

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 98 · see citing works

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study

den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G., van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab172 · Cited by 92 · see citing works

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review

Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 93 · see citing works

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90 · see citing works

The success of SARS-CoV-2 vaccines and challenges ahead

Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 90 · see citing works

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

Favresse, J., Gillot, C., Chiaro, L. D., Eucher, C., Elsen, M., Eeckhoudt, S. V., David, C., Morimont, L., Dogné, J., & Douxfils, J. (2021) · Viruses · doi:10.3390/v13071364 · Cited by 82 · see citing works

Decay of Fc-dependent antibody functions after mild to moderate COVID-19

Lee, W., Selva, K., Davis, S. K., Wines, B., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E., Tan, H.-X., Juno, J., et al. (2020) · medRxiv · doi:10.1016/j.xcrm.2021.100296 · Cited by 84 · see citing works

Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents

Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 72 · see citing works

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

Zhao, F., Zai, X., Zhang, Z., Xu, J., & Chen, W. (2022) · npj Vaccines · doi:10.1038/s41541-022-00597-4 · Cited by 81 · see citing works

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019

Lee, J.-S., Kim, S. Y., Kim, T. S., Hong, K. H., Ryoo, N.-H., Lee, J., Park, J. H., Cho, S. I., Kim, M. J., Kim, Y.-G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1421 · Cited by 73 · see citing works

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Li, C., Yu, D., Wu, X. J., Hong, L., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24230-5 · Cited by 73 · see citing works

Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection

Lin, Y., Wang, G., Shen, Y., Wang, Z.-Y., Zhan, B.-D., Duan, L., Lu, B., Shi, C., Gao, Y., Peng, H.-H., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab255 · Cited by 68 · see citing works

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 66 · see citing works

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Irsara, C., Egger, A., Prokop, W., Nairz, M., Loacker, L., Sahanic, S., Pizzini, A., Sonnweber, T., Holzer, B., Mayer, W., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0214 · Cited by 65 · see citing works

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

Steenhuis, M., van Mierlo, G. J., Derksen, N. I. L., Heer, P. O., Kruithof, S., Loeff, F. C., Berkhout, L. C., Linty, F., Reusken, C. B. E. M., Reimerink, J. H. J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1285 · Cited by 61 · see citing works

Defending against SARS-CoV-2: The T cell perspective

Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 64 · see citing works

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy

Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J., Logue, J. K., Corti, D., et al. (2021) · bioRxiv · doi:10.1371/journal.ppat.1010248 · Cited by 71 · see citing works

Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England

Jeffery-Smith, A., Rowland, T. A. J., Patel, M., Whitaker, H., Iyanger, N., Williams, S. V., Giddings, R., Thompson, L., Zavala, M., Aiano, F., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00253-1 · Cited by 57 · see citing works

Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2

Yu, K. K. Q., Fischinger, S., Smith, M. T., Atyeo, C. G., Cizmeci, D., Wolf, C. R., Layton, E. D., Logue, J. K., Aguilar, M. S., Shuey, K. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146242 · Cited by 54 · see citing works

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 57 · see citing works

Expression and characterization of SARS-CoV-2 spike proteins

Schaub, J. M., Chou, C.-W., Kuo, H.-C., Javanmardi, K., Hsieh, C.-L., Goldsmith, J., DiVenere, A. M., Le, K. C., Wrapp, D., Byrne, P. O., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00623-0 · Cited by 52 · see citing works

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19

Glück, V., Grobecker, S., Tydykov, L., Salzberger, B., Glück, T., Weidlich, T., Bertok, M., Gottwald, C., Wenzel, J. J., Gessner, A., et al. (2021) · Infection · doi:10.1007/s15010-021-01598-6 · Cited by 55 · see citing works

Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2

Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab607 · Cited by 44 · see citing works

Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

Swartz, M. D., DeSantis, S. M., Yaseen, A. S., Brito, F. A., Valerio-Shewmaker, M. A., Messiah, S. E., León‐Novelo, L., Kohl, H. W., Pinzon-Gomez, C. L., Hao, T., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac167 · Cited by 55 · see citing works

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection

Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54 · see citing works

Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation

Struck, F., Schreiner, P. A., Staschik, E., Wochinz‐Richter, K., Schulz, S., Soutschek, E., Motz, M., & Bauer, G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27270 · Cited by 48 · see citing works

Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection

Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.080 · Cited by 55 · see citing works

Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals

Markmann, A., Giallourou, N., Bhowmik, D., Hou, Y., Lerner, A., Martinez, D. R., Premkumar, L., Root, H., van Duin, D., Napravnik, S., et al. (2021) · Msphere · doi:10.1128/msphere.00275-21 · Cited by 55 · see citing works

Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection

Okuya, K., Hattori, T., Saito, T., Takadate, Y., Sasaki, M., Furuyama, W., Marzi, A., Ohiro, Y., Konno, S., Hattori, T., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01553-21 · Cited by 51 · see citing works

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design

Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 50 · see citing works

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis

Muecksch, F., Wise, H., Templeton, K., Batchelor, B., Squires, M., McCance, K., Jarvis, L., Malloy, K., Furrie, E., Richardson, C., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00090-8 · Cited by 34 · see citing works

COVID ‐19 and plasma cells: Is there long‐lived protection?*

Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 44 · see citing works

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice

Loes, A. N., Gentles, L. E., Greaney, A. J., Crawford, K. H. D., & Bloom, J. D. (2020) · Viruses · doi:10.3390/v12090987 · Cited by 44 · see citing works

SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation

Sandberg, J. T., Varnaitė, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., García, M., Dzidic, M., Folkesson, E., Skagerberg, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1306 · Cited by 44 · see citing works

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection

Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S.-L., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2220948120 · Cited by 29 · see citing works

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Cattaneo, C. M., Cancelli, V., Imberti, L., Dobbs, K., Sottini, A., Pagani, C., Belotti, A., Re, A., Anastasia, A., Quaresima, V., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00546-9 · Cited by 39 · see citing works

mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants

Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 38 · see citing works

The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post–COVID-19 Syndrome in Healthcare Workers

Pereira, C., Harris, B. H. L., Giovannantonio, M. D., Rosadas, C., Short, C.-E. S., Quinlan, R. A., Sureda-Vives, M., Fernández, N., Day-Weber, I., Khan, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab120 · Cited by 37 · see citing works

Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership

Herrington, D. M., Sanders, J. W., Wierzba, T. F., Alexander‐Miller, M. A., Espeland, M. A., Bertoni, A. G., Mathews, A., Seals, A. L., Munawar, I., Runyon, M. S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06517-6 · Cited by 35 · see citing works

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34 · see citing works

Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19

Zaidi, S. K., Rizwan, F., Riaz, Q., Siddiqui, A., Khawaja, S., Imam, M., Naz, A., Waheed, S., & Shamsi, T. S. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa170 · Cited by 34 · see citing works

Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration

Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150449 · Cited by 30 · see citing works

Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination

Fernández‐González, M., Agulló, V., Padilla, S., García, J. A., García‐Abellán, J., Botella, Á., Mascarell, P., Ruiz‐García, M., Masiá, M., & Gutiérrez, F. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1021 · Cited by 34 · see citing works

Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection

Yan, L., Liu, P., Li, X.-G., Zhou, S.-J., Li, H., Wang, Z.-Y., Shen, F., Lu, B., Long, Y., Xiao, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.803031 · Cited by 33 · see citing works

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection

Rosati, M., Terpos, E., Ntanasis‐Stathopoulos, I., Agarwal, M., Bear, J., Burns, R. T., Hu, X., Korompoki, E., Donohue, D. E., Venzon, D. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793953 · Cited by 32 · see citing works

Impact of reproduction number on the multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model

Shayak, B., Sharma, M., Gaur, M., & Mishra, A. K. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.018 · Cited by 30 · see citing works

What do we know about the antibody responses to SARS-CoV-2?

Lagunas‐Rangel, F. A., & Chávez‐Valencia, V. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152054 · Cited by 29 · see citing works

SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges

McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 29 · see citing works

Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study

Horton, D. B., Barrett, E. S., Roy, J., Gennaro, M. L., Andrews, T., Greenberg, P. J., Bruiners, N., Datta, P., Ukey, R., Velusamy, S. K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab411 · Cited by 26 · see citing works

The role and uses of antibodies in COVID-19 infections: a living review

Scourfield, D. O., Reed, S. G., Quastel, M. N., Alderson, J., Bart, V. M. T., Crespo, A. T., Jones, R., Pring, E., Richter, F., & Burnell, S. E. A. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab003 · Cited by 30 · see citing works

A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens

Upreti, S., & Samant, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03323-w · Cited by 29 · see citing works

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27 · see citing works

Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile

Law, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 25 · see citing works

A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients

Luo, Y.-Q. R., Yun, C., Chakraborty, I., Wu, A., & Lynch, K. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-21 · Cited by 16 · see citing works

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Vandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27 · see citing works

Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019

Noh, J. Y., Kwak, J.-E., Yang, J., Hwang, S. Y., Yoon, J. G., Seong, H., Hyun, H., Lim, C. S., Yoon, S., Ryou, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab124 · Cited by 24 · see citing works

Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis

Savage, H. R., Santos, V. S., Edwards, T., Giorgi, E., Krishna, S., Planche, T., Staines, H. M., Fitchett, J. R. A., Kirwan, D. E., Cubas-Atienzar, A. I., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009551 · Cited by 26 · see citing works

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 27 · see citing works

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021

Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 25 · see citing works

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes

Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 27 · see citing works

Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays

Renard, N., Daniel, S., Cayet, N., Pecquet, M., Raymond, F., Pons, S., Lupo, J., Tourneur, C., Pretis, C., Gerez, G., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02292-20 · Cited by 26 · see citing works

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2

Guenthoer, J., Garrett, M. E., Lilly, M., Depierreux, D., Ruiz, F., Chi, M., Stoddard, C. I., Chohan, V., Yaffe, Z. A., Sung, K., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012383 · Cited by 24 · see citing works

Effect of ArtemiC in patients with COVID‐19: A Phase II prospective study

Hellou, E., Mohsin, J., Elemy, A., Hakim, F., Hellou, M. M., & Hamoud, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17337 · Cited by 22 · see citing works

Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., Holubar, M. K., et al. (2022) · eLife · doi:10.7554/elife.77943 · Cited by 29 · see citing works

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

Palumbo, G. A., Cambria, D., Spina, E. L., Duminuco, A., Laneri, A., Longo, A., Vetro, C., Giallongo, S., Romano, A., Raimondo, F. D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117815 · Cited by 21 · see citing works

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21 · see citing works

Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study

Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21 · see citing works

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 154 · see citing works

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patientsPreprint

Chansaenroj, J., Yorsaeng, R., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripram, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., Saiyarin, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1073046/v1 · Cited by 3 · see citing works

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1143 · Cited by 218 · see citing works

Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection

Choe, P. G., Kang, C. K., Suh, H. J., Jung, J., Song, K., Bang, J. H., Kim, E. S., Kim, H. B., Park, S., Kim, N. J., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2701.203515 · Cited by 122 · see citing works

Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2

Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab607 · Cited by 44 · see citing works